Date: November 7, 2021
Time: 8:00am (PST), 11:00am (EST)
Analysis of SARS-CoV-2–specific T cells is important to understand their role during acute disease and in long-term protection after infection or vaccination. Though studying these rare cells comes with challenges, gained insights offer great opportunities in fighting COVID-19. This webinar will cover both sides.
There is growing evidence that SARS-CoV-2–specific T cells play an important role in the recovery from COVID-19. Researchers have reported the presence of a SARS-CoV-2–specific memory T cell population in the blood of convalescent donors. These cells could be used for treating COVID-19 patients in certain cases.
At Miltenyi Biotec, we offer a complete workflow for the study of virus-specific T cells. Also, several preparation methods for clinical-grade cell products using our CliniMACS® Technology have been described.1-3 In 2021, Antonio Perez et al. reported improvement of symptoms in nine patients in a phase 1 clinical trial using convalescent donor-derived CD45RA-depleted memory T cells. The study indicates the potential of adoptive cell therapy to treat COVID-19.4 More research is needed to further develop this new exciting field of cell therapy.
1 Cooper et al. (2021) Front. Immunol. 11: 598402. 2 Leung et al. (2020) Adv. Cell Gene Ther. 2020: e101. 3 Ferreras et al. (2021) Front. Cell Dev. Biol. 9: 620730. 4 Pérez-Martínez et al. (2021) EClinicalMedicine 39: 101086.
- Review tools for SARS-CoV-2–specific T cell research
- Discuss how to overcome key challenges, such as high sample numbers, low cell frequencies, inefficient stimulation, and operator safety
- Review published preclinical and clinical data on cell therapy for COVID-19
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.